These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 16301833)

  • 1. Managing patients treated with bevacizumab combination therapy.
    Gordon MS; Cunningham D
    Oncology; 2005; 69 Suppl 3():25-33. PubMed ID: 16301833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.
    Hurwitz H; Saini S
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S26-34. PubMed ID: 17145522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anti-angiogenic treatment and colorectal cancer].
    André T; Tournigand C; Abbas F; Louvet C; de Gramont A;
    Bull Cancer; 2007 Jul; 94 Spec No():S211-9. PubMed ID: 17846007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing patients with metastatic colorectal cancer on bevacizumab.
    Lemmens L; Claes V; Uzzell M
    Br J Nurs; 2008 Aug 14-Sep 10; 17(15):944-9. PubMed ID: 18983014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
    Sogabe S; Komatsu Y; Yuki S; Kusumi T; Hatanaka K; Nakamura M; Kato T; Miyagishima T; Hosokawa A; Iwanaga I; Sakata Y; Asaka M
    Jpn J Clin Oncol; 2011 Apr; 41(4):490-7. PubMed ID: 21303790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of bevacizumab in patients with metastatic breast cancer.
    Hamilton EP; Blackwell KL
    Oncology; 2011; 80(5-6):314-25. PubMed ID: 21778772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse events in bevacizumab and chemotherapy: patient management.
    Blowers E; Hall K
    Br J Nurs; 2009 Apr 9-22; 18(7):424-8. PubMed ID: 19373187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intricacies of bevacizumab-induced toxicities and their management.
    Gressett SM; Shah SR
    Ann Pharmacother; 2009 Mar; 43(3):490-501. PubMed ID: 19261963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing adverse events in the use of bevacizumab and chemotherapy.
    Blowers E; Hall K
    Br J Nurs; 2009 Mar 26-Apr 8; 18(6):351-6, 358. PubMed ID: 19329899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer.
    Krämer I; Lipp HP
    J Clin Pharm Ther; 2007 Feb; 32(1):1-14. PubMed ID: 17286784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nursing considerations of bevacizumab use in multiple tumor types.
    Gobel BH
    Oncol Nurs Forum; 2007 May; 34(3):693-701. PubMed ID: 17573328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.
    Scappaticci FA; Fehrenbacher L; Cartwright T; Hainsworth JD; Heim W; Berlin J; Kabbinavar F; Novotny W; Sarkar S; Hurwitz H
    J Surg Oncol; 2005 Sep; 91(3):173-80. PubMed ID: 16118771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer.
    Akun E; Okutur K; Seber S; Korkmaz T; Aydin K; Bozkurt M; Namal E; Hasbal B; Tecimer C; Demir G
    J BUON; 2012; 17(4):669-76. PubMed ID: 23335523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab and ovarian cancer.
    Sato S; Itamochi H
    Curr Opin Obstet Gynecol; 2012 Feb; 24(1):8-13. PubMed ID: 22123222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
    Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
    Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging safety data for bevacizumab in advanced non-small-cell lung cancer.
    Hirsh V
    Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S62-70. PubMed ID: 21885001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
    Chase JL
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab safety in Japanese patients with colorectal cancer.
    Hatake K; Doi T; Uetake H; Takahashi Y; Ishihara Y; Shirao K
    Jpn J Clin Oncol; 2016 Mar; 46(3):234-40. PubMed ID: 26774113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrointestinal perforation due to bevacizumab in colorectal cancer.
    Saif MW; Elfiky A; Salem RR
    Ann Surg Oncol; 2007 Jun; 14(6):1860-9. PubMed ID: 17356952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.